Stellar signs distributor for Uracyst in Portugal

Stellar Pharmaceuticals’ (OTCBB: SLXCF) Uracyst drug for interstitial cystitis/painful bladder syndrome will be distributed in Portugal by CPH Companhia Portuguesa Higiene, a specialty pharma company with a major focus in urology, the primary target market for Uracyst. “Expanding the global licensing of Uracyst is a major growth driver for Stellar,” CEO, Peter Riehl, said in [...]

Watson has high hopes for Stellar’s Uracyst drug

Watson Pharmaceuticals (NYSE:WPI) CEO, Paul Bisaro, painted a rosy picture of how Stellar Pharmaceuticals’ (OTCBB: SLXCF) Uracyst drug, which is indicated to treat interstitial cystitis, fills out its urology strategy. According to a presentation at a healthcare conference sponsored by Barclays Capital, Mr. Bisaro said that Watson’s strategy is based on the 10 most common [...]

Stellar outlines strategy at Cowen conference; gets Chinese patent

Upcoming milestones for Stellar Pharmaceuticals (OTCBB:SLXCF) provide for near-and mid-term investment triggers, President and CEO, Peter Riehl, said in a presentation at the SG Cowen healthcare conference in Boston. Stellar, which is only one of three Canadian companies presenting at the Cowen conference, is aggressively expanding its global out-licensing programs for its two lead products [...]

Stellar plugging bladder wall around the world

In 2003, Lana Tenney began chemotherapy following her breast cancer surgery.  And as stressful as that was, things quickly worsened.  She developed a side-effect from chemotherapy called cystitis, a painful bladder condition that oncologists see in 10%-to-15% of cancer patients, who feel an urge to urinate 20-to-30 times a day, whether they can or can’t. [...]

Stellar results from Stellar Pharmaceuticals

London-Ont.-based Stellar Pharmaceuticals (OTCBB:SLXCF) reported strong third quarter financial results today. The company’s revenues grew by 71.9%, driven by 7.9% and 303.1% growth in Canadian and International sales, respectively.   Net income grew by 42.9%.   This was the fourth consecutive quarter Stellar has generated a profit. Stellar has developed and is marketing direct in Canada and in [...]

Stellar gets South Korea distributor for Uracyst

Stellar Pharmaceuticals (OTCBB:SLXCF) has signed a licensing agreement for the distribution and sale of one of its lead products, Uracyst, to treat interstitial cystitis/painful bladder syndrome in South Korea with Jeilmedix Pharmaceutical. Peter Riehl, Stellar’s CEO, said in a statement that the accord is in line with the company’s strategy of selling direct in Canada [...]

« Previous Page